Grafa News and Videos — Page 514

Workforce solutions provider Atlantic International (NASDAQ:ATLN) reported first-quarter 2026 revenue of $249.9 million.

Biopharmaceutical firm Nuvectis (NASDAQ:NVCT) licensed exclusive ex-China rights for two clinical drug assets in a deal valued up to $1.461 billion.

Biotechnology firm bioAffinity Technologies (NASDAQ:BIAF) announced preclinical findings showing its novel small interfering RNA therapeutic approach selectively destroys cells from two common skin cancers that affect an estimated 5.4 million annual United States cases.

Booz Allen Hamilton (NYSE:BAH) executed a definitive agreement to acquire Ultra I&C Mission Solutions for $720 million to expand its defense technology portfolio.

Worksport (NASDAQ:WKSP) announced a preliminary gross margin of approximately 35% for the month of May 2026.

Outdoor Holding Company (NASDAQ:POWW) reported a 10.1% increase in fourth-quarter revenue to $13.9 million.

Palvella Therapeutics (NASDAQ:PVLA) announced that the FDA granted rolling review for its rare genetic disease drug application.

Organon (NYSE:OGN) finalized a global licensing agreement with Sebela Pharmaceuticals for a hormone-free birth control device that is 99% effective.

REGENXBIO (NASDAQ:RGNX) aligned with the FDA to resubmit its rare disease drug application in Q3 2026.

MapLight (NASDAQ:MPLT) announced that its Phase 2 autism trial of 161 patients missed its primary efficacy endpoint.